JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return

Why It Matters

Novo’s rapid uptake signals accelerating patient preference for oral weight‑loss drugs, while Lilly’s delay highlights regulatory bottlenecks that could reshape competitive timelines. The IPO revival reflects renewed investor confidence in biotech pipelines after a year of uncertainty.

Key Takeaways

• Novo's oral Wegovy treated 3,100 patients within first week
• Lilly's orforglipron FDA decision delayed to April 10
• CNPV program aims to accelerate review to 1‑2 months
• IPO activity resurges with SpyGlass and AgomAb listings
• Obesity market competition intensifies amid MFN pricing debate

Pulse Analysis

The obesity treatment landscape is entering a new phase as oral formulations gain traction. Novo Nordisk’s Wegovy pill, launched on Jan. 5, has already been prescribed to nearly 3,100 patients, a pace that outstrips many injectable counterparts. This rapid adoption reflects both patient convenience and the company’s aggressive rollout strategy, positioning Novo as a front‑runner in a market projected to exceed $30 billion by 2030. Analysts note that oral delivery could broaden access, especially in primary‑care settings where injections remain a barrier.

Regulatory timing remains a critical variable for competitors. Eli Lilly’s oral GLP‑1 candidate, orforglipron, was slated for an FDA decision on March 28 but has been postponed to April 10 under the Commissioner’s National Priority Voucher (CNPV) scheme. While the voucher promises a compressed review window of one to two months, recent delays affecting other voucher recipients suggest that the program’s speed advantage is not guaranteed. The postponement gives Lilly additional time to refine its data package but also cedes early market momentum to Novo, potentially influencing pricing negotiations and payer adoption curves.

Investor sentiment at JPM2026 signaled a rebound in capital markets for biotech firms. The listings of SpyGlass Pharma and AgomAb Therapeutics, alongside earlier entrants like Veradermics, illustrate renewed appetite for high‑growth, specialty‑focused companies. Coupled with policy debates around the administration’s Most Favored Nation drug‑pricing framework, the resurgence of IPOs suggests confidence that innovative pipelines—particularly in obesity and metabolic disease—can deliver robust returns despite regulatory headwinds. Stakeholders will watch closely how pricing reforms and FDA timelines intersect to shape the competitive arena over the next twelve months.